With zero revenue and zero gross profit across all reported quarters, the income statement shows operating losses widening from -$1.2M in 2024Q2 to -$2.8M in 2026Q2 with no margin base to evaluate.
Eocene Ltd. (EOCN) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.04M | 1.08M | 467K | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | -100% | 87.83% | 132.33% | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50K | 9K | 4K | 5K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.04M | 1.08M | 467K | -50K | -9K | -4K | -5K |
| Gross Margin % | - | - | - | - | - | - | - | - | 100% | 100% | 100% | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | -100% | 87.83% | 132.33% | 1034% | -455.56% | -125% | 20% | - |
| Operating Expenses | 9.96M | 8.51M | 6.28M | 7.49M | 17.65M | 32.88M | 30.21M | 22.38M | 12.75M | 13.45M | 17.35M | 10.82M | 9.13M | 14.56M | 3.13M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | 625.76% | 1239.54% | 3714.99% | - | - | - | - |
| Selling, General & Admin | 3.63M | 3.64M | 3.3M | 3.92M | 4.66M | 5.66M | 4.13M | 4.2M | 4.44M | 3.8M | 3.08M | 3.2M | 2.47M | 7.35M | 689K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | 217.86% | 350.14% | 659.1% | - | - | - | - |
| Research & Development | 6.32M | 4.87M | 2.98M | 3.57M | 12.99M | 27.22M | 26.08M | 18.18M | 8.31M | 9.65M | 14.27M | 7.63M | 6.66M | 7.21M | 2.44M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | 407.9% | 889.4% | 3055.89% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -9.96M | -8.51M | -6.28M | -7.49M | -17.65M | -32.88M | -30.21M | -22.38M | -10.71M | -12.36M | -16.88M | -10.88M | -9.14M | -14.56M | -3.14M |
| Operating Margin % | - | - | - | - | - | - | - | - | -525.76% | -1139.54% | -3614.99% | - | - | - | - |
| Operating Income Growth % | - | -35.55% | 16.2% | 57.55% | 46.32% | -8.84% | -35.01% | -108.83% | 13.34% | 26.76% | -55.24% | -18.96% | 37.22% | -364.2% | - |
| EBITDA | -11.53M | -10.31M | -6.2M | -7.46M | -17.62M | -32.84M | -30.17M | -22.34M | -10.33M | -12.13M | -16.71M | -10.82M | -9.13M | -14.56M | -3.13M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -506.77% | -1117.51% | -3578.8% | - | - | - | - |
| EBITDA Growth % | -39.34% | -66.41% | 16.97% | 57.65% | 46.36% | -8.84% | -35.05% | -116.31% | 14.82% | 27.45% | -54.39% | -18.53% | 37.26% | -364.81% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 83K | 31K | 35K | 42K | 39K | 35K | 387K | 239K | 169K | 50K | 9K | 4K | 5K |
| EBIT | -11.53M | -10.31M | -7.5M | -6.9M | -17.65M | -32.42M | -30.21M | -22.38M | -10.71M | -12.36M | -16.88M | -10.88M | -9.14M | -14.56M | -3.14M |
| Net Interest Income | 800K | 914K | 488K | 364K | 82K | 519K | 1.16M | 1.88M | 917K | 153K | 315K | 0 | 0 | -34K | 6 |
| Interest Income | 902K | 914K | 503K | 375K | 297K | 562K | 1.19M | 1.92M | 959K | 65K | 35K | 253K | 40K | 0 | 6 |
| Interest Expense | 102K | 0 | 15K | 11K | 215K | 43K | 31K | 33K | 42K | 49K | 67K | 0 | 0 | 34K | 0 |
| Other Income/Expense | -1.39M | -1.8M | -1.24M | 580K | -215K | 414K | 1.44M | 1.92M | 934K | 65K | 35K | 253K | 40K | -2.92M | -6K |
| Pretax Income | -11.34M | -10.31M | -7.52M | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.78M | -12.3M | -16.85M | -10.62M | -9.1M | -17.48M | -3.14M |
| Pretax Margin % | - | - | - | - | - | - | - | - | -479.93% | -1133.55% | -3607.49% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75K | 0 | 106K | 0 | 1K | 1K | 6K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.77% | 0% | -0.63% | 0% | -0.01% | -0.01% | -0.19% |
| Net Income | -11.34M | -10.31M | -7.52M | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.86M | -12.3M | -16.95M | -10.62M | -9.1M | -17.48M | -3.15M |
| Net Margin % | - | - | - | - | - | - | - | - | -483.61% | -1133.55% | -3630.19% | - | - | - | - |
| Net Income Growth % | -30.05% | -37.14% | -8.75% | 61.31% | 44.97% | -12.85% | -40.61% | -107.6% | 19.86% | 27.45% | -59.6% | -16.69% | 47.94% | -455.26% | - |
| Net Income (Continuing) | -11.34M | -10.31M | -7.52M | -6.91M | -17.87M | -32.47M | -28.77M | -20.46M | -9.86M | -12.3M | -16.95M | -10.62M | -9.1M | -17.48M | -3.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -11.91 | -19.12 | -64.64 | -239.60 | -88.64 | -155.84 | -155.68 | -105.36 | -65.20 | -118.16 | -178.88 | -14.35 | -13.23 | -24.57 | -9.32 |
| EPS Growth % | 97.71% | 70.42% | 73.02% | -170.31% | 43.12% | -0.1% | -47.76% | -61.6% | 44.82% | 33.94% | -1146.55% | -8.47% | 46.15% | -163.63% | - |
| EPS (Basic) | - | -19.12 | -64.64 | -240.40 | -88.64 | -155.84 | -155.68 | -105.36 | -65.20 | -118.16 | -178.88 | -14.35 | -13.23 | -24.57 | -9.32 |
| Diluted Shares Outstanding | 952.17K | 538.91K | 116.35K | 28.85K | 209.52K | 204.98K | 177.34K | 175.95K | 151.15K | 104.06K | 94.79K | 740.03K | 688.25K | 711.66K | 337.96K |
| Basic Shares Outstanding | 952.17K | 538.91K | 116.35K | 28.75K | 209.52K | 204.98K | 177.34K | 175.95K | 151.15K | 104.06K | 94.79K | 740.03K | 688.25K | 711.66K | 337.96K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying EOCN stock.
For fiscal year 2025, Eocene Ltd. (EOCN) reported total revenue of $0.0M.
Eocene Ltd. (EOCN) reported a net loss of $10.3M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Persistent operating losses without revenue
Pre-Revenue Profile With No Top-Line Base
Based on EOCN's reported quarterly figures, no revenue or cost of goods sold has been recorded across the ten quarters from 2024Q1 through 2026Q2, leaving growth-rate analysis unavailable for the period.
The absence of reported revenue means revenue growth cannot be measured, and the income statement reflects a development-stage cost base rather than a commercial operation. This suggests the company's economics currently depend on R&D progress and external funding rather than sales traction. Investors should monitor for any first revenue recognition, which would be the first observable test of commercial viability.
R&D-Led Spending Shapes the Loss Profile
As reported in EOCN's quarterly statements, R&D expense rose from $534.0K in 2024Q2 to $1.8M in 2026Q2, becoming the dominant operating cost line in recent periods.
R&D has grown faster than SG&A over the recent window, with SG&A ranging roughly between $572K and $1.3M without a clear trend. This pattern suggests spending is being directed toward clinical or technical development rather than commercial infrastructure. Whether this allocation is appropriate depends on pipeline milestones that the income statement alone cannot confirm.
Operating Losses Show No Scaling Benefit
Based on EOCN's reported figures, operating loss widened from -$1.2M in 2024Q2 to -$2.8M in 2026Q2 with no gross profit offset, indicating no operating leverage is yet observable.
With gross profit at zero, operating leverage in the conventional sense cannot be assessed, and the cost base has expanded rather than being absorbed by revenue. The recent quarters show losses roughly doubling against the early-period baseline. This may indicate that cost growth is outpacing any path to commercial scale, warranting further investigation of spending guidance.
Share Count Volatility Distorts Per-Share Losses
According to reported EPS, diluted loss per share swung from -$1.84 in 2024Q1 to -$371.36 in 2024Q4, a movement that appears driven by share count changes rather than operating performance alone.
Net loss figures moved within a comparatively narrow range while EPS varied enormously, suggesting material changes in the share base, possibly from reverse splits or capital raises. Such variability makes per-share trend analysis unreliable for this period. Investors should examine share count disclosures before drawing conclusions from EPS trajectory.
Sustained Losses Could Erode Funding Runway
Based on reported figures, cumulative quarterly net losses across the ten periods exceed $20M while revenue remains zero, raising questions about how long current resources can sustain operations without additional capital.
The counter-argument is that the company may be forced into dilutive financing, which the EPS volatility already hints at. Stock-based compensation of roughly $100K to $240K per quarter adds a non-cash cost but does not change the underlying cash burn implication. Without disclosed cash balances in the supplied data, the funding risk remains an inference that warrants verification against the balance sheet.